Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy

Scandinavian Journal of Urology

Volumn 47, Issue 6, 2013, Pages 456-461

  Vasarainen, Hanna ^a   Lahdensuo, Kanerva ^a   Savolainen, Ritja ^a   Ruutu, Mirja ^a   Taari, Kimmo ^a   Rannikko, Antti ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Active surveillance; Diffusion weighted MRI; MRI; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PROGNOSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE VOLUME; PROSTATECTOMY;

AGED; BIOPSY; CARCINOMA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84890450975     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2013.765910     Document Type: Article

References (29)

1. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29: 3669-76.
2. Futterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-80.
3. Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol 2009;50:562-9.
4. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174:2158-63.
5. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusionweighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007;42:842-7.
6. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009;44:572-6.
7. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009;55:801-14.
8. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, et al. A study of diffusionweighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009;56:981-8.
9. Morgan VA, Riches SF, Thomas K, Vanas N, Parker C, Giles S, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011;84:31-7.
10. deSouza NM, Riches SF, van As NJ, Morgan VA, Ashley SA, Fisher C, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008;63:774-82.
11. van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS Study. Eur Urol 2007;52:1560-3.
12. Afaq A, Koh D, Padhani A, van As N, Sohaib SA. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011;108:1716-22.
13. Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206.
14. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61:297-302.
15. Raz O, Haider M, Trachtenberg J, Leibovici D, Lawrentschuk N. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010;7:543-51.
16. Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259:775-84.
17. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011;186: 1818-24.
18. Hoeks CMA, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SWTPJ, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261:46-66.
19. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010;194: W316-22.
20. Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000;56:617-21.
21. Mazal PR, Haitel A, Windischberger C, Djavan B, Sedivy R, Moser E, et al. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001;39:662-8.
22. Iremashvili V, Pelaez L, Jorda M, Manoharan M, Arianayagam M, Rosenberg DL, et al. Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology 2012; 79:37-42.
23. Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999;161:494-9.
24. Mayes JM, Mouraviev V, Sun L, Tsivian M, Madden JF, Polascik TJ. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol 2011;29:166-70.
25. Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A, et al. Unilateral prostate cancer cannot be accurately predicted in low-risk patients. Int J Radiat Oncol Biol Phys 2010;77:784-7.
26. Gregori A, Vieweg J, Dahm P, Paulson DF. Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site. Urol Int 2001;66:66-71.
27. Guzzo TJ, Resnick MJ, Canter DJ, Bivalacqua TJ, Rosen MA, Bergey MR, et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance. Urol Oncol 2012;30: 301-5.
28. Lawrence EM, Gnanapragasam VJ, Priest AN, Sala E. The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol 2012;9:94-101.
29. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477-94.